Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2014 (2014), Article ID 274584, 11 pages
http://dx.doi.org/10.1155/2014/274584
Research Article

HLA-G Expression Is an Independent Predictor for Improved Survival in High Grade Ovarian Carcinomas

1Academic Medical Center, Center of Gynaecologic Oncology, Amsterdam, The Netherlands
2Department of Pathology, Academic Medical Center, Amsterdam, The Netherlands
3Free University Medical Center, Center of Gynaecologic Oncology, Amsterdam, The Netherlands

Received 7 January 2014; Accepted 28 March 2014; Published 27 May 2014

Academic Editor: Nathalie Rouas-Freiss

Copyright © 2014 M. J. Rutten et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Siegel, D. Naishadham, and A. Jemal, “Cancer statistics, 2012,” CA Cancer Journal for Clinicians, vol. 62, no. 1, pp. 10–29, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Elattar, A. Bryant, B. A. Winter-Roach, M. Hatem, and R. Naik, “Optimal primary surgical treatment for advanced epithelial ovarian cancer,” Cochrane Database of Systematic Reviews, no. 8, p. CD007565, 2011. View at Google Scholar · View at Scopus
  3. E.-I. Braicu, J. Sehouli, R. Richter, K. Pietzner, C. Denkert, and C. Fotopoulou, “Role of histological type on surgical outcome and survival following radical primary tumour debulking of epithelial ovarian, fallopian tube and peritoneal cancers,” British Journal of Cancer, vol. 105, no. 12, pp. 1818–1824, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. W. E. Winter III, G. L. Maxwell, C. Tian et al., “Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group study,” Journal of Clinical Oncology, vol. 26, no. 1, pp. 83–89, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. R. J. Kurman and I.-M. Shih, “Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer—shifting the paradigm,” Human Pathology, vol. 42, no. 7, pp. 918–931, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. R. J. Kurman and I.-M. Shih, “Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications,” International Journal of Gynecological Pathology, vol. 27, no. 2, pp. 151–160, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Bamias, M. Sotiropoulou, F. Zagouri et al., “Prognostic evaluation of tumour type and other histopathological characteristics in advanced epithelial ovarian cancer, treated with surgery and paclitaxel/carboplatin chemotherapy: cell type is the most useful prognostic factor,” European Journal of Cancer, vol. 48, pp. 1476–1483, 2012. View at Google Scholar
  8. R. Vang, I.-M. Shih, and R. J. Kurman, “Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems,” Advances in Anatomic Pathology, vol. 16, no. 5, pp. 267–282, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Shehata, A. Mukherjee, S. Deen, A. Al-Attar, L. G. Durrant, and S. Chan, “Human leukocyte antigen class i expression is an independent prognostic factor in advanced ovarian cancer resistant to first-line platinum chemotherapy,” British Journal of Cancer, vol. 101, no. 8, pp. 1321–1328, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. B. Seliger, Y. Rongcun, D. Atkins et al., “HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes,” International Journal of Cancer, vol. 87, pp. 349–359, 2000. View at Google Scholar
  11. N. F. S. Watson, J. M. Ramage, Z. Madjd et al., “Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis,” International Journal of Cancer, vol. 118, no. 1, pp. 6–10, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Gooden, M. Lampen, E. S. Jordanova et al., “HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8+ T lymphocytes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 26, pp. 10656–10661, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. Z. Madjd, I. Spendlove, S. E. Pinder, I. O. Ellis, and L. G. Durrant, “Total loss of MHC class I is an independent indicator of good prognosis in breast cancer,” International Journal of Cancer, vol. 117, no. 2, pp. 248–255, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. Y. Wook Jung, Y. Tae Kim, S. Wun Kim et al., “Correlation of human leukocyte antigen-g (hla-g) expression and disease progression in epithelial ovarian cancer,” Reproductive Sciences, vol. 16, no. 11, pp. 1103–1111, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Suthanthiran and T. B. Strom, “Medical progress: renal transplantation,” The New England Journal of Medicine, vol. 331, no. 6, pp. 365–375, 1994. View at Publisher · View at Google Scholar · View at Scopus
  16. B. Favier, J. LeMaoult, and E. D. Carosella, “Functions of HLA-G in the immune system,” Tissue Antigens, vol. 69, no. 1, pp. 150–152, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. N. Rouas-Freiss, P. Moreau, C. Menier, and E. D. Carosella, “HLA-G in cancer: a way to turn off the immune system,” Seminars in Cancer Biology, vol. 13, no. 5, pp. 325–336, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. V. M. Braud, A. J. McMichael, and V. Cerundolo, “Differential processing of influenza nucleoprotein in human and mouse cells,” European Journal of Immunology, vol. 28, pp. 625–635, 1998. View at Google Scholar
  19. N. Lee, M. Llano, M. Carretero et al., “HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 9, pp. 5199–5204, 1998. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Moretta, R. Biassoni, C. Bottino, M. C. Mingari, and L. Moretta, “Natural cytotoxicity receptors that trigger human NK-cell-mediated cytolysis,” Immunology Today, vol. 21, no. 5, pp. 228–234, 2000. View at Publisher · View at Google Scholar · View at Scopus
  21. K.-J. Malmberg, V. Levitsky, H. Norell et al., “IFN-γ protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism,” Journal of Clinical Investigation, vol. 110, no. 10, pp. 1515–1523, 2002. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Lin, W.-H. Yan, H.-H. Xu et al., “HLA-G expression in human ovarian carcinoma counteracts NK cell function,” Annals of Oncology, vol. 18, no. 11, pp. 1804–1809, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. F.-A. Le Gal, B. Riteau, C. Sedlik et al., “HLA-G-mediated inhibition of antigen-specific cytotoxic T lymphocytes,” International Immunology, vol. 11, no. 8, pp. 1351–1356, 1999. View at Publisher · View at Google Scholar · View at Scopus
  24. P. Contini, M. Ghio, A. Poggi et al., “Soluble HLA-A,-B,-C and -G molecules induce apoptosis in T and NK CD8+ cells and inhibit cytotoxic T cell activity through CD8 ligation,” European Journal of Immunology, vol. 33, no. 1, pp. 125–134, 2003. View at Publisher · View at Google Scholar · View at Scopus
  25. P. Rolland, S. Deen, I. Scott, L. Durrant, and I. Spendlove, “Human leukocyte antigen class I antigen expression is an independent prognostic factor in ovarian cancer,” Clinical Cancer Research, vol. 13, no. 12, pp. 3591–3596, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. L. Han, M. S. Fletcher, D. L. Urbauer et al., “HLA class i antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma,” Clinical Cancer Research, vol. 14, no. 11, pp. 3372–3379, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. L. M. Real, T. Cabrera, A. Collado et al., “Expression of HLA G in human tumors is not a frequent event,” International Journal of Cancer, vol. 81, pp. 512–518, 1999. View at Google Scholar
  28. M. Urosevic, M. O. Kurrer, J. Kamarashev et al., “Human leukocyte antigen G up-regulation in lung cancer associates with high-grade histology, human leukocyte antigen class I loss and interleukin-10 production,” The American Journal of Pathology, vol. 159, no. 3, pp. 817–824, 2001. View at Google Scholar · View at Scopus
  29. S. Lefebvre, M. Antoine, S. Uzan et al., “Specific activation of the non-classical class I histocompatibility HLA-G antigen and expression of the ILT2 inhibitory receptor in human breast cancer,” Journal of Pathology, vol. 196, no. 3, pp. 266–274, 2002. View at Publisher · View at Google Scholar · View at Scopus
  30. N. Rouas-Freiss, S. Bruel, C. Menier, C. Marcou, P. Moreau, and E. D. Carosella, “Switch of HLA-G alternative splicing in a melanoma cell line causes loss of HLA-G1 expression and sensitivity to NK lysis,” International Journal of Cancer, vol. 117, no. 1, pp. 114–122, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. B. Davidson, M. B. Elstrand, M. T. McMaster et al., “HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma,” Gynecologic Oncology, vol. 96, no. 1, pp. 42–47, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. F. A. El-Chennawi, F. A. Auf, A. M. El-Diasty et al., “Expression of HLA-G in cancer bladder,” The Egyptian Journal of Immunology, vol. 12, no. 1, pp. 57–64, 2005. View at Google Scholar · View at Scopus
  33. M. Urosevic and R. Dummer, “HLA-G and IL-10 expression in human cancer—different stories with the same message,” Seminars in Cancer Biology, vol. 13, no. 5, pp. 337–342, 2003. View at Publisher · View at Google Scholar · View at Scopus
  34. S. Agaugué, E. D. Carosella, and N. Rouas-Freiss, “Role of HLA-G in tumor escape through expansion of myeloid-derived suppressor cells and cytokinic balance in favor of Th2 versus Th1/Th17,” Blood, vol. 117, no. 26, pp. 7021–7031, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. J. Bukur, S. Jasinski, and B. Seliger, “The role of classical and non-classical HLA class I antigens in human tumors,” Seminars in Cancer Biology, vol. 22, pp. 350–358, 2012. View at Google Scholar
  36. S. Gluck, S. F. de, J. Peeters, L. Stork-Sloots, and G. Somlo, “Molecular subtyping of early-stage breast cancer identifies a group of patients who do not benefit from neoadjuvant chemotherapy,” Breast Cancer Research and Treatment, vol. 139, pp. 759–767, 2013. View at Google Scholar
  37. C. Menier, S. Prevot, E. D. Carosella, and N. Rouas-Freiss, “Human leukocyte antigen-G is expressed in advanced-stage ovarian carcinoma of high-grade histology,” Human Immunology, vol. 70, no. 12, pp. 1006–1009, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. A. N. Gordon, M. Tonda, S. Sun, and W. Rackoff, “Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer,” Gynecologic Oncology, vol. 95, no. 1, pp. 1–8, 2004. View at Publisher · View at Google Scholar · View at Scopus
  39. J. A. Rauh-Hain, C. C. Nitschmann, J. Worley et al., “Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma,” Gynecologic Oncology, vol. 129, pp. 63–68, 2013. View at Google Scholar
  40. M. Vitale, G. Pelusi, B. Taroni et al., “HLA class I antigen down-regulation in primary ovary carcinoma lesions: association with disease stage,” Clinical Cancer Research, vol. 11, no. 1, pp. 67–72, 2005. View at Google Scholar · View at Scopus
  41. F. Garrido and I. Algarra, “MHC antigens and tumor escape from immune surveillance,” Advances in Cancer Research, vol. 83, pp. 117–158, 2001. View at Publisher · View at Google Scholar · View at Scopus
  42. E. M. De Kruijf, A. Sajet, J. G. H. Van Nes et al., “HLA-E and HLA-G expression in classical HLA class I-negative tumors is of prognostic value for clinical outcome of early breast cancer patients,” Journal of Immunology, vol. 185, no. 12, pp. 7452–7459, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. E. C. Zeestraten, M. S. Reimers, S. Saadatmand et al., “Combined analysis of HLA class I, HLA-E and HLA-G predicts prognosis in colon cancer patients,” British Journal of Cancer, vol. 110, pp. 459–468, 2013. View at Publisher · View at Google Scholar
  44. G. Singer, V. Rebmann, Y.-C. Chen et al., “HLA-G is a potential tumor marker in malignant ascites,” Clinical Cancer Research, vol. 9, no. 12, pp. 4460–4464, 2003. View at Google Scholar · View at Scopus
  45. I.-M. Shih and R. J. Kurman, “Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis,” The American Journal of Pathology, vol. 164, no. 5, pp. 1511–1518, 2004. View at Google Scholar · View at Scopus
  46. S. Rajagopalan and E. O. Long, “KIR2DL4 (CD158d): an activation receptor for HLA-G,” Frontiers in Immunology, vol. 3, 258 pages, 2012. View at Google Scholar
  47. A. Lin, H. H. Xu, D. P. Xu, X. Zhang, Q. Wang, and W. H. Yan, “Multiple steps of HLA-G in ovarian carcinoma metastasis: alter NK cytotoxicity and induce matrix metalloproteinase-15 (MMP-15) expression,” Human Immunology, vol. 74, pp. 439–446, 2013. View at Google Scholar
  48. S. Coupel, A. Moreau, M. Hamidou, V. Horejsi, J.-P. Soulillou, and B. Charreau, “Expression and release of soluble HLA-E is an immunoregulatory feature of endothelial cell activation,” Blood, vol. 109, no. 7, pp. 2806–2814, 2007. View at Publisher · View at Google Scholar · View at Scopus
  49. E. D. Carosella, B. Favier, N. Rouas-Freiss, P. Moreau, and J. Lemaoult, “Beyond the increasing complexity of the immunomodulatory HLA-G molecule,” Blood, vol. 111, no. 10, pp. 4862–4870, 2008. View at Publisher · View at Google Scholar · View at Scopus
  50. S. A. O'Toole, B. L. Sheppard, A. Laios et al., “Potential predictors of chemotherapy response in ovarian cancer-How do we define chemosensitivity?” Gynecologic Oncology, vol. 104, no. 2, pp. 345–351, 2007. View at Publisher · View at Google Scholar · View at Scopus
  51. P. Schütt, B. Schütt, M. Switala et al., “Prognostic relevance of soluble human leukocyte antigen-G and total human leukocyte antigen class I molecules in lung cancer patients,” Human Immunology, vol. 71, no. 5, pp. 489–495, 2010. View at Publisher · View at Google Scholar · View at Scopus
  52. X. He, D.-D. Dong, S.-M. Yie et al., “HLA-G expression in human breast cancer: implications for diagnosis and prognosis, and effect on allocytotoxic lymphocyte response after hormone treatment in vitro,” Annals of Surgical Oncology, vol. 17, no. 5, pp. 1459–1469, 2010. View at Publisher · View at Google Scholar · View at Scopus
  53. B.-L. Li, A. Lin, X.-J. Zhang et al., “Characterization of HLA-G expression in renal cell carcinoma,” Tissue Antigens, vol. 74, no. 3, pp. 213–221, 2009. View at Publisher · View at Google Scholar · View at Scopus
  54. A. Lin, X. Zhang, W.-J. Zhou et al., “Human leukocyte antigen-G expression is associated with a poor prognosis in patients with esophageal squamous cell carcinoma,” International Journal of Cancer, vol. 129, no. 6, pp. 1382–1390, 2011. View at Publisher · View at Google Scholar · View at Scopus